Markel Group Inc. Has $20.09 Million Stake in Thermo Fisher Scientific Inc. $TMO

Markel Group Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,550 shares of the medical research company’s stock after purchasing an additional 4,550 shares during the quarter. Markel Group Inc.’s holdings in Thermo Fisher Scientific were worth $20,091,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Mendel Money Management boosted its holdings in Thermo Fisher Scientific by 4.4% during the second quarter. Mendel Money Management now owns 11,304 shares of the medical research company’s stock worth $4,583,000 after purchasing an additional 475 shares during the last quarter. First Pacific Advisors LP acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $35,425,000. New York Life Investment Management LLC lifted its stake in Thermo Fisher Scientific by 0.4% in the second quarter. New York Life Investment Management LLC now owns 51,393 shares of the medical research company’s stock valued at $20,838,000 after acquiring an additional 214 shares during the last quarter. Private Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 7.2% in the second quarter. Private Wealth Partners LLC now owns 64,700 shares of the medical research company’s stock valued at $26,233,000 after acquiring an additional 4,342 shares during the last quarter. Finally, Howard Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 29.0% in the second quarter. Howard Capital Management Inc. now owns 2,979 shares of the medical research company’s stock valued at $1,209,000 after acquiring an additional 670 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $558.18 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $506.77 and a two-hundred day simple moving average of $455.26. The stock has a market capitalization of $210.77 billion, a price-to-earnings ratio of 32.25, a price-to-earnings-growth ratio of 3.30 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the company earned $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This represents a 5.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares in the company, valued at approximately $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 54,420 shares of company stock valued at $28,134,684. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent analyst reports. Barclays increased their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. TD Cowen increased their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. HSBC reiterated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company increased their price objective on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $594.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.